Contraception for individuals with sickle cell disease: a systematic review of the literature

Abstract Background Women with sickle cell disease have an increased risk of pregnancy-related complications and need safe, effective contraceptive methods to prevent unintended pregnancy. Study Design We conducted a systematic review to examine the safety of hormonal and intrauterine contraceptive...

Full description

Saved in:
Bibliographic Details
Published in:Contraception (Stoneham) 2012-06, Vol.85 (6), p.527-537
Main Authors: Haddad, Lisa B, Curtis, Kathryn M, Legardy-Williams, Jennifer K, Cwiak, Carrie, Jamieson, Denise J
Format: Article
Language:English
Subjects:
Anemia, Sickle Cell - complications
Anemias. Hemoglobinopathies
Biological and medical sciences
Complications
Contraception
Contraception - adverse effects
Contraception - methods
contraceptives
Contraceptives, Oral, Combined - adverse effects
Contraceptives, Oral, Hormonal - adverse effects
Diseases of red blood cells
Female
Genital system. Reproduction
Gynecology. Andrology. Obstetrics
Hematologic and hematopoietic diseases
Hormonal
Humans
Medical sciences
MEDLINE
Obstetrics and Gynecology
Pharmacology. Drug treatments
Pregnancy
Pregnancy Complications - prevention & control
Pregnancy Complications, Hematologic - prevention & control
Progestins - adverse effects
Reviews
Risk Factors
Sickle cell anemia
Systematic review
Thromboembolism - chemically induced
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Women with sickle cell disease have an increased risk of pregnancy-related complications and need safe, effective contraceptive methods to prevent unintended pregnancy. Study Design We conducted a systematic review to examine the safety of hormonal and intrauterine contraceptive use among women with sickle cell disease. Results Eight articles met the inclusion criteria. The evidence was of fair to poor quality and suggested that progestin-only and combined hormonal contraception had no effect on frequency of sickle crises or other adverse events and no effect on hematologic parameters associated with sickle crises. No studies examined the risk of thromboembolism in combined hormonal contraceptive users with sickle cell disease. There was insufficient evidence to comment on the safety of intrauterine contraception. Conclusion While data are limited, there is no evidence to suggest that hormonal contraceptive use among women with sickle cell disease is associated with an increased risk of clinical complications.
ISSN:0010-7824
1879-0518
DOI:10.1016/j.contraception.2011.10.008